Bitopertin + Placebo + SSRI
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Obsessive-Compulsive Disorder
Conditions
Obsessive-Compulsive Disorder
Trial Timeline
Dec 31, 2012 → Apr 30, 2015
NCT ID
NCT01674361About Bitopertin + Placebo + SSRI
Bitopertin + Placebo + SSRI is a phase 2 stage product being developed by Roche for Obsessive-Compulsive Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT01674361. Target conditions include Obsessive-Compulsive Disorder.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01674361 | Phase 2 | Completed |
Competing Products
8 competing products in Obsessive-Compulsive Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| pregabalin + Placebo | Pfizer | Approved | 84 |
| Sertraline + Levetiracetam + Placebo | UCB | Phase 2/3 | 62 |
| Escitalopram + Placebo oral tablet | Lundbeck | Approved | 82 |
| Valbenazine + Placebo | Neurocrine Biosciences | Phase 2 | 49 |
| Troriluzole + Placebo | Biohaven | Phase 3 | 72 |
| Troriluzole + Placebo | Biohaven | Phase 3 | 72 |
| Troriluzole + Placebo | Biohaven | Phase 2/3 | 60 |
| Nitrous Oxide + Nitrogen | Brain Biotech | Phase 2 | 44 |